NC-LENOVO
10.11.2021 15:02:09 CET | Business Wire | Press release
Lenovo™ today announced that DreamWorks Animation has selected Lenovo as its preferred workstation innovation partner to deliver the high-end power and performance needed to bring its next cutting-edge animation feature films to life. This PC collaboration further strengthens the companies’ partnership, as it expands upon the technology leader’s current role as DreamWorks’ data center innovation partner. As part of this multi-year agreement, DreamWorks will deploy Lenovo workstations, including the ThinkStation P620 and ThinkStation P920 , across all departments for the development of content and characters, including the highly anticipated release of the studio’s upcoming film, “The Bad Guys.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005429/en/
The extension of this partnership follows the rollout of a new on-premises Lenovo computing infrastructure designed to transform DreamWorks’ data center into a high-performance, ultra-scalable and sustainable operations center for all of its content creation.
With consumer demand for premium animated content at an all-time high, DreamWorks Animation looked to Lenovo’s Intelligent Devices Group to find innovative workstation solutions that could keep up with its ever-scaling ambitions, increasingly complex workflows and faster production timelines. Designed for high productivity, Lenovo workstations are engineered for power, performance and industry-leading reliability that allow artists to bring their creative ideas to life.
“At DreamWorks, the ability to operate our workflows at the speed of our creative thought process is critical in capturing those instant moments of expression that shape the unforgettable experiences our animators and creative professionals develop. Workstations need to exceed the demands of our artists’ relentless imaginations. Hardware needs to be an enabler; harnessing performance and speed to meet their expectations,” said Bill Ballew, Chief Technology Officer at DreamWorks. “We had the opportunity to test Lenovo’s ThinkStation P620 workstation and realized it’s a game changer for our workflows. Built on the AMD Ryzen™ Threadripper™ PRO architecture, the ThinkStation P620 drives new and improved performance for multi-threaded application environments that our team can take full advantage of.”
From 3D modeling, rigging, surfacing, and simulations to high performance animation and creating hyper-photorealistic renderings, DreamWorks Animation specialists, artists and engineers alike leverage high performance compute capabilities. By relying on the flexibility and future-proofed platforms that Lenovo’s workstations deliver, the DreamWorks’ team can focus on their creative ambitions knowing they are equipped with the world-class technology necessary to meet those complex workflows - now and in the years ahead. In addition to the Lenovo ThinkStation P620, DreamWorks Animation will also be able to take advantage of Lenovo’s most advanced dual processor workstation, the ThinkStation P920. Built with the latest generation of Intel® Xeon® processors, the workstation’s extreme performance will help DreamWorks accelerate their most challenging workflows in a production studio environment.
“We’re excited to expand our partnership with DreamWorks Animation and equip them with workstations that help accelerate their increasingly demanding workflows,” said Rob Herman, Vice President of Lenovo’s Workstation and Client AI Business Unit. “Our workstation collaboration further exemplifies Lenovo’s ability to holistically support our customers with the most advanced technology solutions available, allowing them to innovate faster and transform their respective industries.”
To learn more about how DreamWorks Animation is strengthening its partnership with Lenovo to bring about the next evolution of production, visit: https://techtoday.lenovo.com/us/en/workstations
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. AMD and RYZEN™ are trademarks of Advanced Micro Devices, Inc. Intel, Intel Core and vPro are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. ©2021, Lenovo Group Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005429/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom